Discover open access scientific publications

Search, annotate, share and cite publications

Publications by A. Cova

P2.04-11 an IL-8/IFN-gammma/NLR Plasma Score to Predict Nivolumab Efficacy in Patients With NSCLC

Journal of Thoracic Oncology

English

Related publications

P2.04-10 Early Monitoring of Blood Biomarkers to Predict Nivolumab Efficacy in NSCLC Patients

Journal of Thoracic Oncology

English

Baseline Neutrophil-To-Lymphocyte Ratio (NLR) and Derived NLR Could Predict Overall Survival in Patients With Advanced Melanoma Treated With Nivolumab

Journal for ImmunoTherapy of Cancer

English

P2.04-02 Predictive Value of Circulating Tumor Cells and Circulating Free DNA in NSCLC Patients Treated With Nivolumab

Journal of Thoracic Oncology

English

Plasma Levels of IL-8 Predict Early Complications in Patients With Coronary Heart Disease After Percutaneous Coronary Intervention

Japanese Heart Journal

2003

English

Elevated Plasma Concentrations of IL-6 and Elevated APACHE II Score Predict Acute Kidney Injury in Patients With Severe Sepsis

Clinical Journal of the American Society of Nephrology

Intensive Care Medicine

2006

English

P2.04-12 a Genomic Signature [JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2] Predicts Baseline Resistance to Nivolumab in Advanced NSCLC.

Journal of Thoracic Oncology

English

182P: Intracranial Response to Nivolumab in NSCLC Patients With Untreated or Progressing CNS Metastases

Journal of Thoracic Oncology

English

Figure 3: Plasma IFN-γ, TNF-α, and IL-17 Levels in Patients With OA.

English

P2.13-27 Development, Internal Validation, and Calibration of a Risk Score to Predict Survival in Patients With EGFR Mutant NSCLC

Journal of Thoracic Oncology

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by A. Cova

P2.04-11 an IL-8/IFN-gammma/NLR Plasma Score to Predict Nivolumab Efficacy in Patients With NSCLC

Related publications

P2.04-10 Early Monitoring of Blood Biomarkers to Predict Nivolumab Efficacy in NSCLC Patients

Baseline Neutrophil-To-Lymphocyte Ratio (NLR) and Derived NLR Could Predict Overall Survival in Patients With Advanced Melanoma Treated With Nivolumab

P2.04-02 Predictive Value of Circulating Tumor Cells and Circulating Free DNA in NSCLC Patients Treated With Nivolumab

Plasma Levels of IL-8 Predict Early Complications in Patients With Coronary Heart Disease After Percutaneous Coronary Intervention

Elevated Plasma Concentrations of IL-6 and Elevated APACHE II Score Predict Acute Kidney Injury in Patients With Severe Sepsis

P2.04-12 a Genomic Signature [JAK2, JAK3, PIAS4, PTPN2, STAT3, IFNAR2] Predicts Baseline Resistance to Nivolumab in Advanced NSCLC.

182P: Intracranial Response to Nivolumab in NSCLC Patients With Untreated or Progressing CNS Metastases

Figure 3: Plasma IFN-γ, TNF-α, and IL-17 Levels in Patients With OA.

P2.13-27 Development, Internal Validation, and Calibration of a Risk Score to Predict Survival in Patients With EGFR Mutant NSCLC